Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD

BACKGROUND: Formoterol fumarate inhalation solution (FFIS; Perforomist(®)) is a long-acting β(2)-agonist (LABA) marketed in the US as a nebulized COPD maintenance treatment. Because long-term LABA use was associated with a potential increased risk of exacerbation or death in asthma patients, the US...

全面介紹

Na minha lista:
書目詳細資料
發表在:Int J Chron Obstruct Pulmon Dis
Main Authors: Hanania, Nicola A, Sethi, Sanjay, Koltun, Arkady, Ward, Jonathan K, Spanton, Jacqui, Ng, Dik
格式: Artigo
語言:Inglês
出版: Dove Medical Press 2018
主題:
Original Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6311322/
https://ncbi.nlm.nih.gov/pubmed/30643398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S173595
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍